Published in Urol Oncol on February 03, 2010
Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer. Cancer (2016) 1.39
Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol (2011) 1.21
Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. Urol Oncol (2016) 0.76
Female with bladder cancer: what and why is there a difference? Transl Androl Urol (2016) 0.75
Retrospective analysis of a surgical innovation using the IDEAL framework: radical cystectomy with epidural anaesthesia. J Int Med Res (2017) 0.75
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol (2008) 5.64
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol (2009) 4.27
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol (2012) 3.12
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol (2008) 2.88
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. J Urol (2010) 2.61
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Complications after radical and partial nephrectomy as a function of age. J Urol (2010) 2.36
Defining optimal therapy for muscle invasive bladder cancer. J Urol (2007) 2.30
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol (2011) 2.22
Surgical practice patterns for male urinary incontinence: analysis of case logs from certifying American urologists. J Urol (2012) 2.20
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08
Management of low grade papillary bladder tumors. J Urol (2007) 2.04
Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol (2004) 1.99
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol (2012) 1.95
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol (2010) 1.88
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol (2007) 1.87
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis (2009) 1.86
Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol (2010) 1.79
A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int (2006) 1.79
Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits? J Urol (2010) 1.78
A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int (2008) 1.76
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer (2008) 1.62
Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur Urol (2008) 1.61
Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology (2007) 1.60
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Recovery of renal function after open and laparoscopic partial nephrectomy. Eur Urol (2010) 1.53
Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomy. Urology (2012) 1.50
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol (2004) 1.50
Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy. Eur Urol (2012) 1.50
Is it necessary to remove the seminal vesicles completely at radical prostatectomy? decision curve analysis of European Society of Urologic Oncology criteria. J Urol (2008) 1.50
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol (2010) 1.48
Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol (2010) 1.47
The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery. Health Qual Life Outcomes (2011) 1.41
Sexual dysfunction is common and overlooked in female patients with hypertension. J Sex Marital Ther (2002) 1.40
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38
Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol (2010) 1.38
Modelling wetland bird response to water level changes in the Lake Ontario - St. Lawrence River hydrosystem. Environ Monit Assess (2006) 1.37
Metastatic renal cell carcinoma risk according to tumor size. J Urol (2009) 1.35
Radical nephrectomy with vena caval thrombectomy: a contemporary experience. BJU Int (2010) 1.32
The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol (2010) 1.30
Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer. J Clin Oncol (2013) 1.30
Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol (2006) 1.29
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol (2010) 1.27
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun (2003) 1.19
Adolescent varicocelectomy--is the potential for catch-up growth related to age and/or Tanner stage? J Urol (2008) 1.17
Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int (2009) 1.13
Prostate size is associated with surgical difficulty but not functional outcome at 1 year after radical prostatectomy. J Urol (2009) 1.09
Quality control in transurethral resection of bladder tumours. BJU Int (2008) 1.08
Association between younger age when first overweight and increased risk for CKD. J Am Soc Nephrol (2013) 1.08
Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. Ann Intern Med (2014) 1.05
Recovery of urinary function after radical prostatectomy: predictors of urinary function on preoperative prostate magnetic resonance imaging. J Urol (2012) 1.05
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer (2010) 1.03
Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol (2003) 1.03
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology (2007) 1.02
Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol (2002) 1.01
Use of Amplatz sheath in male urethra during cystolitholapaxy of large bladder calculi. Urology (2004) 1.00
Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant (2008) 1.00
Sexual function following bowel vaginoplasty. J Urol (2006) 0.99
Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int (2006) 0.98
The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. BJU Int (2015) 0.97
Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer. Mol Biol Int (2012) 0.96
Sclerosing Sertoli cell tumor without expression of typical sex cord stromal tumor markers: case report and literature review. Pathol Res Pract (2012) 0.95
Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer (2006) 0.93
Natural history of positive urinary cytology after radical cystectomy. J Urol (2006) 0.93
Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma. J Urol (2011) 0.93
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol (2007) 0.92
Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma cases. J Urol (2010) 0.91
Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J Urol (2004) 0.90
A plea for a uniform surveillance schedule after radical cystectomy. J Urol (2011) 0.90
Low birth weight, later renal function, and the roles of adulthood blood pressure, diabetes, and obesity in a British birth cohort. Kidney Int (2013) 0.89
Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage III lung cancer. J Thorac Oncol (2014) 0.88
Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int (2013) 0.88
Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? J Urol (2005) 0.88
Placement of transileal conduit retrograde nephroureteral stents in patients with ureteral obstruction after cystectomy: technique and outcome. AJR Am J Roentgenol (2008) 0.87
Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha). J Cancer Res Clin Oncol (2002) 0.87
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin Cancer Res (2013) 0.86
Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer (2013) 0.86